Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
5.78
+0.07 (1.23%)
At close: Apr 28, 2026, 4:00 PM EDT
5.89
+0.11 (1.90%)
After-hours: Apr 28, 2026, 4:29 PM EDT
Passage Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Passage Bio stock have an average target of 14, with a low estimate of 7.00 and a high estimate of 23. The average target predicts an increase of 142.21% from the current stock price of 5.78.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Passage Bio stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 21, 2026 |
| Chardan Capital | Chardan Capital | Strong Buy → Hold Downgrades $21 → $7 | Strong Buy → Hold | Downgrades | $21 → $7 | +21.11% | Apr 21, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $30 → $15 | Buy | Maintains | $30 → $15 | +159.52% | Apr 21, 2026 |
| Wedbush | Wedbush | Buy → Hold Downgrades $32 → $8 | Buy → Hold | Downgrades | $32 → $8 | +38.41% | Apr 21, 2026 |
| Oppenheimer | Oppenheimer | Buy Initiates $30 | Buy | Initiates | $30 | +419.03% | Mar 31, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-8.75
from -14.35
EPS Next Year
-8.45
from -8.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.18 | -2.37 | ||||||
| Avg | -8.75 | -8.45 | ||||||
| Low | -13.94 | -18.74 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.